Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $11.40 Average Target Price from Analysts

by · The Cerbat Gem

Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $11.40.

A number of research analysts have recently weighed in on the company. HC Wainwright cut their price target on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. B. Riley lowered Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $16.00 to $2.00 in a research note on Wednesday, August 7th. Maxim Group decreased their target price on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Finally, StockNews.com upgraded shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 8th.

View Our Latest Analysis on ATNM

Actinium Pharmaceuticals Stock Performance

Actinium Pharmaceuticals stock opened at $1.68 on Friday. The firm has a 50-day moving average price of $1.84. The company has a market capitalization of $50.04 million, a PE ratio of -0.98 and a beta of 0.14. Actinium Pharmaceuticals has a 12-month low of $1.33 and a 12-month high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.02. Research analysts predict that Actinium Pharmaceuticals will post -1.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company acquired a new stake in Actinium Pharmaceuticals during the 2nd quarter worth approximately $92,000. Squarepoint Ops LLC bought a new stake in shares of Actinium Pharmaceuticals during the second quarter worth $356,000. Marshall Wace LLP raised its holdings in shares of Actinium Pharmaceuticals by 67.9% during the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after acquiring an additional 103,557 shares during the period. Renaissance Technologies LLC bought a new stake in Actinium Pharmaceuticals in the 2nd quarter valued at $142,000. Finally, Rhumbline Advisers boosted its stake in Actinium Pharmaceuticals by 23.4% in the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares during the period. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

(Get Free Report

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).

Further Reading